[Skip to Content]
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
[Skip to Content Landing]
Views 158
Citations 0
Correction
June 15, 2020

Error in Figure

JAMA Neurol. Published online June 15, 2020. doi:10.1001/jamaneurol.2020.2025

In the Original Investigation titled “Safety, Tolerability, and Efficacy of Viltolarsen in Boys With Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping: A Phase 2 Randomized Clinical Trial,”1 published online May 26, 2020, there was an error in Figure 3. In panel C, the CINRG DNHS line should be 0.42 at the week 13 visit and 0.74 at the week 25 visit. This article was corrected online.

References
1.
Clemens  PR, Rao  VK, Connolly  AM,  et al; CINRG DNHS Investigators.  Safety, tolerability, and efficacy of viltolarsen in boys with Duchenne muscular dystrophy amenable to exon 53 skipping: a phase 2 randomized clinical trial.   JAMA Neurol. Published online May 26, 2020. doi:10.1001/jamaneurol.2020.1264Google Scholar
×